The Emerging Role of p27 in Development of Diseases
DOI:
https://doi.org/10.17140/CSMMOJ-4-e006Abstract
The cell cycle regulation and tumor suppressor p27 encoded by CDKN1B plays a key role in many cellular events.1-3 p27 is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors, which functions to negatively regulate cell cycle progression at the G1/S boundary in response to antiproliferative stimuli. In addition, numerous p27 functions, not related to CDK inhibition, have been described. For instance, cytosolic p27 plays a role in the regulation of cytoskeleton assembly/disassembly, therefore, regulates the cell morphology and movement. In addition, p27 is involved in apoptosis and autophagy modulation.
References
Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008; 8(4): 253-267. doi: 10.1038/nrc2347
Bencivenga D, Caldarelli I, Stampone E, et al. p27(Kip1) and hu-man cancers: A reappraisal of a still enigmatic protein. Cancer Lett. 2017; 403: 354-365. doi: 10.1016/j.canlet.2017.06.031
Wander SA, Zhao D, Slingerland JM. p27: A barometer of sig-naling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res. 2011; 17(1): 12-18. doi: 10.1158/1078- 0432.CCR-10-0752
Jia W, He M-X, McLeod IX, Guo J, Ji D, He Y-W. Autophagy regulates T lymphocyte proliferation through selective degradation of the cell-cycle inhibitor CDKN1B/p27Kip1. Autophagy. 2015; 11(12): 2335-2345. doi: 10.1080/15548627.2015.1110666
Sun X, Momen A, Wu J, et al. p27 protein protects metaboli-cally stressed cardiomyocytes from apoptosis by promoting au-tophagy. J Biol Chem. 2014; 289(24):16924-16935. doi: 10.1074/jbc. M113.542795
Levkau B, Koyama H, Raines EW, et al. Cleavage of p21Cip1/ Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell. 1998; 1(4): 553-563. doi: 10.1016/s1097-2765(00)80055-6
Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential me-diator of extracellular antimitogenic signals. Cell. 1994; 78(1): 59- 66. doi: 10.1016/0092-8674(94)90572-x
Occhi G, Regazzo D, Trivellin G, et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 2013; 9(3): e1003350. doi: 10.1371/ journal.pgen.1003350
Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A Somatic mutation and germline sequence abnormalities in CD-KN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2011; 96(4): E701-E706. doi: 10.1210/ jc.2010-1338
Dietrich S, Hüllein J, Lee SC, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015; 126(8): 1005-1008. doi: 10.1182/blood-2015-04-643361
Stephens PJ, Tarpey PS, Davies H, et al. The landscape of can-cer genes and mutational processes in breast cancer. Nature. 2012; 486(7403): 400-404. doi: 10.1038/nature11017
Maxwell JE, Sherman SK, Li G, et al. Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tu-mors. Cancer Genet. 2015; pii: S2210-S7762(15): 00184-00192. doi: Editorial | Volume 4 | Number 1| Cancer Stud Mol Med Open J. 2018; 4(1): e1-e2. doi: 10.17140/CSMMOJ-4-e006 10.1016/j.cancergen.2015.08.003
Crona J, Gustavsson T, Norlén O, et al. Somatic mutations and genetic heterogeneity at the CDKN1B locus in small intestinal neuroendocrine tumors. Ann Surg Oncol. 2015; 22 Suppl 3: S1428- S1435. doi: 10.1245/s10434-014-4351-9
Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013; 45(12): 1483-1486. doi: 10.1038/ng.2821
Viglietto G, Motti ML, Fusco A. Understanding p27(kip1) de-regulation in cancer: Down-regulation or mislocalization. Cell Cycle. 2002; 1(6): 394-400. doi: 10.4161/cc.1.6.263
Masciullo V, Sgambato A, Pacilio C, et al. Frequent loss of ex-pression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 1999; 59(15): 3790-3794.
Loda M, Cukor B, Tam SW, et al. Increased proteasome-de-pendent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997; 3(2): 231-234. doi: 10.1038/nm0297-231
McCampbell AS, Mittelstadt ML, Dere R, et al. Loss of p27 as-sociated with risk for endometrial carcinoma arising in the setting of obesity. Curr Mol Med. 2016; 16(3): 252-265. doi: 10.2174/1566 524016666160225153307
Singh SP, Lipman J, Goldman H, et al. Loss or altered subcel-lular localization of p27 in Barrett’s associated adenocarcinoma. Cancer Res. 1998; 58(8): 1730-1735.
Sgambato A, Ratto C, Faraglia B, et al. Reduced expression and altered subcellular localization of the cyclin-dependent kinase in-hibitor p27(Kip1) in human colon cancer. Mol Carcinog. 1999; 26(3): 172-179. doi: 10.1002/(SICI)1098-2744(199911)26:3<172::AID-MC6>3.0.CO;2-8
Shehata MA, Nosseir HR, Nagy HM, Farouk G. Cyclin depen-dent kinase inhibitor p27(kip1) expression and subcellular localiza-tion in relation to cell proliferation in hepatocellualr carcinoma. Egypt J Immunol. 2006; 13(1): 115-130.
Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization Editorial | Volume 4 | Number 1| Yang Q, et al and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002; 8(10): 1136-1144. doi: 10.1038/nm762
Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implica-tions in primary breast cancer. Nat Med. 1997; 3(2): 227-230.
McCampbell AS, Walker CL, Broaddus RR, Cook JD, Davies PJ. Developmental reprogramming of IGF signaling and suscepti-bility to endometrial hyperplasia in the rat. Lab Invest. 2008; 88(6): 615-626. doi: 10.1038/labinvest.2008.29
Oshita F, Kameda Y, Nishio K, et al. Increased expression lev-els of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep. 2000; 7(3): 491-495. doi: 10.3892/or.7.3.491
Korkolopoulou P1, Vassilopoulos I, Konstantinidou AE, et al. The combined evaluation of p27Kip1 and Ki-67 expression pro-vides independent information on overall survival of ovarian car-cinoma patients. Gynecol Oncol. 2002; 85(3): 404-414. doi: 10.1006/ gyno.2002.6627
Han S, Park K, Kim HY, et al. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast can-cer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat. 1999; 55(2): 161-167. doi: 10.1023/a:1006258222233
Moreno-Galindo C, Hermsen M, García-Pedrero JM, et al. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2014; 50(2): 128- 134. doi: 10.1016/j.oraloncology.2013.10.018
Cook JD, Davis BJ, Cai SL, Barrett JC, Conti CJ, Walker CL. Interaction between genetic susceptibility and early-life environ-mental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A. 2005; 102(24): 8644-8649. doi: 10.1073/ pnas.0503218102
Mas A, Stone L, O’Connor PM. Developmental exposure to endocrine disruptors expands murine myometrial stem cell com-partment as a prerequisite to leiomyoma tumorigenesis. stem cells. 2017; 35(3): 666-678. doi: 10.1002/stem.2519 e3
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
